ArticleCureus2026
Cardiovascular Risks Associated With Cannabis Use Among ED Patients.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives Cannabis is one of the most widely used psychoactive substances, and many adults meet the criteria for Cannabis Use Disorder (CUD). Prior research on its association with cardiovascular disease (CVD) has yielded mixed results. This study evaluates the relationship between CUD and CVD among ED patients. Methods This retrospective, propensity-matched analysis examined records from 67 US healthcare organizations (HCOs) in the TriNetX database from 2005 to 2022. Adult ED patients with CUD documented within five years before or one month after an ED visit were compared with those without CUD. A secondary analysis compared patients with CUD to those with alcohol-related disorders (ARD). Outcomes included all-cause mortality, stroke, and myocardial infarction (MI) within three years of the ED visit. Matching controlled for demographics and comorbidities. Results A total of 1,748,263 ED patients were identified. After propensity matching, 598,114 adult patients remained, with 299,057 in each of the CUD and no-CUD groups. Patients with CUD experienced higher rates of mortality (RR 1.69, 95% CI 1.64-1.75) and MI (RR 1.07, 95% CI 1.02-1.12) within three years compared with those without CUD, with no significant difference in stroke (RR 0.96, 95% CI 0.90-1.02). In the secondary analysis, patients with CUD showed lower mortality but higher rates of stroke and MI than those with ARD. Conclusion Cannabis use was associated with increased risks of mortality and MI within three years of an ED visit. These findings add to the existing literature on the cardiovascular implications of cannabis use and may help inform health policy and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.